Fibrosis, closely related to chronic various diseases, is a pathological process characterised by the accumulation of
collagen (largely
collagen type I). Non-invasive methods are necessary for the diagnosis and follow-up of
fibrosis. This study aimed to develop a
collagen-targeted probe for the molecular imaging of
fibrosis. We identified CPKESCNLFVLKD (CBP1495) as an original
collagen-binding
peptide using isothermal titration calorimetry and
enzyme-linked
immunosorbent assay. CBP1495 effectively bound to
collagen type I (K d = 861 nM) and (GPO)9 (K d = 633 nM), a
collagen mimetic
peptide. Western blot and histochemistry validated CBP1495 targeting
collagen in vitro and ex vivo. (Gly-(D)-
Ala-Gly-Gly) was introduced to CBP1495 for coupling 99mTc. Labelling efficiency of 99mTc-CBP1495 was 95.06 ± 1.08 %. The physico-chemical properties, tracer kinetics and biodistribution of 99mTc-CBP1495 were carried out, and showed that the
peptide stably chelated 99mTc in vitro and in vivo. SPECT/CT imaging with 99mTc-CBP1495 was performed in rat
fibrosis models, and revealed that 99mTc-CBP1495 significantly accumulated in fibrotic lungs or livers of rats. Finally, 99mTc-CBP1495 uptake and
hydroxyproline (Hyp), a specific
amino acid of
collagen, were quantitatively analysed. The results demonstrated that 99mTc-CBP1495 uptake was positvely correlated with Hyp content in lungs (P < 0.0001, r 2 = 0.8266) or livers (P < 0.0001, r 2 = 0.7581). Therefore, CBP1495 is a novel
collagen-binding
peptide, and 99mTc-labelled CBP1495 may be a promising radiotracer for the molecular imaging of
fibrosis.